OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-03-31-accounts

ANNUAL REPORT CONTENTS
INTRODUCTION
TRUSTEES' REPORT INCORPORATING THE STRATEGIC REPORT
STATEMENT OF RESPONSIBILITIES OF THE TRUSTEES OF JOHN INNES CENTRE IN
RESPECT OF THE TRUSTEES' ANNUAL REPORT AND THE FINANCIAL STATEMENTS 19
INDEPENDENT
AUDITOR'S REPORT TO THE MEMBERS OF THE JOHN INNES CENTRE		 20
FINANCIAL STATEMENTS 23
NOTES TO THE ACCOUNTS 26
CHARITY INFORMATION 43

STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT
The Trustee Directors consider that the decisions they have made during
the financial year have satisfied the
requirements ofs172(1)ofthe Companies
Act 2006 and that they have acted in good faith to promote the success
ofJICas a whole, and
in doing so having
regard to the stakeholders
and matters
outlined
in s172(1).
The Governing Council has the ultimate
responsibility
for		 the strategy ofJIC and delivery of its charitable
objectives. The table below sets out JIC's most significant stakeholders,
why they are considered
important
and
how the Institute engages.
&We are committed
to providing
a		 &During the year, regular communications
to
supportive,
inspirational
and dynamic		 employees
have been provided
on matters
environment
for our staff and students		 to affecting them,
including
factors affecting
meet future scientific and societal the Charity's
progress,
and have been
challenges. consulted
on decisions that impact them.
kWe value the diversity ofour staff, and k All groups ofstaff and students
have
are committed
to the creation ofa		 representation
on the Inclusivity
8 Diversity
positive environment
which is fair,		 Committee
that meets 4times a year to
welcoming
and inclusive
and where		 ensure an inclusive
research culture
everyone
is treated
with dignity and		 &Students'
progress
is monitored
on a
respect. regular basis and employees
undertake
an
&We are committed
to the development		 of annual
appraisal
where their training
needs,
all our staff and students
and providing		 work-life balance and career development
equal opportunities
that encourage		 are discussed.
flexible working, career development and
work-life balance.
&JIG's corporate
members
are UK		 &The Members each nominate
one
Research and Innovation
(UKRI); John		 Governing
Council member
and appoint
Innes Foundation
(JIF);and the		 one "observer" to attend
Governing
Council
University
ofEast Anglia (UEA). Our		 meetings,
enabling
them to participate
in
members
are key strategic partners		 that key decisions.
oversee our delivery against charitable
objectives.
kJIC is one of4 independent,
world-class		 k The Institute
Directors ofthe 4 institutes
research
institutes
based at the Norwich		 meet regularly
to discuss common strategic
Research Park. The Institutes
work		 and operational
matters.
closely together to create a unique centre &JIC, the other Institutes,
UKRI, UEA, JIF
ofexcellence
in plant and microbial		 and the N8 NU Hospital Trust are members
sciences, big data science and ofAnglia
Innovation
Partnership
LLP, an
genomics,
and food and health.		 organisation
established
to promote
collaborative
solutions to global challenges
in food and health.
&JIG is strategically
funded,
along with		 7 &UKRI nominates
a Governing
Council
other institutes,
by the Biotechnology		 and member
and appoints
an "observer" to
Biological Sciences Research Council attend
Governing
Council meetings.
(BBSRC),part of UKRI. BBSRC &JIC holds regular meetings
with BBSRCto
supports JIC via strategic 5-year funding review and progress ofthe Institute's
programmes,
competitively
won project		 mission and science programmes,
including
grants
and capital funding
for		 strategic and financial
plans.
infrastructure
and technology
investments.
&JIC is an international
centre of plant		 and &An extensive
programme
ofengagement
microbial research. Our success is built with our new collaborative
vision, Healthy
on our collaborations
and our		 Plants, Healthy People, Healthy
Planet
international
outlook.		 (HP3) is ongoing
and involves discussion,
&JIC is home to a range ofstate-of-the-art input and views from stakeholders
from
facilities and technology
platforms
to		 industry,
government
and research
support scientists across the UK. partners,
locally, nationally
and
internationally.
JIC has strategic
partnerships
with research and academic
institutions
in the UK and worldwide,
including
Europe, China, Africa, Brazil and
India.
&JIG works closely with &JIG works closely with industry industry and the &JIG maintains
a dialogue
with industry,
with
private sector to provide access to our regular consultations
and knowledge
capabilities,
and to deliver		 sophisticated exchange.
interdisciplinary research and product &JIG supports
industry
through
collaborative
development at pace. and sponsored
research
and access to its
facilities and plafform services. JIC is
proactive
in identifying
and responding
to
industry
need.
&JIG protects
its innovations
and promotes
their commercialisation
and adoption
by
Industry.
&JIF nominates
an industry
representative
as
an "observer" to attend
Governing
Council
meetings.
&Public views are at the heart of our &JIC staff and students
are trained
in public
research strategy
and		 engaging with the engagement
and communications
and are
public is an important part ofour mission supported
to attend events, use digital
statement. media and to discuss and engage the public
with our research.
kJIC hosts and attends
community
events—
online,
locally and nationally,
to showcase,
debate and discuss the nature ofour
research.
&JICscientists are engaged
in policy
discussions
at a national
level surrounding
the use ofgenetic technologies
for crop
improvement.
kJIC is investing
heavily
in more energy
efficient facilities to reduce utilities
consumption
and waste.
&JIC seeks to maintain and develop &JIC holds regular meetings
with suppliers
strong, open, collaborative relationships about purchasing
relationships
and ethical
with our supply chain. behaviours
such as adherence
to Modern
Slave
rinci les.

RISKASSESSMENT AND MANAGEMENT RISKASSESSMENT AND MANAGEMENT RISKASSESSMENT AND MANAGEMENT RISKASSESSMENT AND MANAGEMENT RISKASSESSMENT AND MANAGEMENT
Governing Council is responsible
for ensuring
there		 are effective and adequate
risk management
and internal
control systems
in place and confirm that the major		 risks to which the Institute
is exposed have been reviewed		 and
procedures established
to manage those risks. The Audit Committee
agrees an annual
risk-based
internal
audit
plan which covers major risks identified
by management		 and Trustees.
It receives reports from internal
auditors		 on
the effectiveness of internal
controls, progress against the		 internal
audit plan and progress on recommendations
made
in reports.		 Governing
Council reviews a full risk report annually,
including
a 'heat map' tracking
major		 risks.
The Science and Impact Advisory
Board (SIAB)assess		 the science quality
and vision section ofthe risk register.
Principal risks and uncertainties
& BBSRCstrategic funding
is reduced		 & Regular
monitoring
ofscientific performance,
including
as a result ofpoor performance
or		 consideration
from the Science and Impact Advisory
Board.
public sector spending
pressures.		 & Regular engagement
with BBSRCto report performance		 and
&JIC is too reliant on BBSRCstrategic ensure strategic alignment
of research
programmes.
and grant funding & Monitoring
ofperformance
ofgrant submissions.
& Funding
opportunities
for other research bodies and charities
regularly
communicated
to Group Leaders.
& Philanthropic
Fundraising
strategy
being developed
to support
NGI plus strategic research activity.
& The focus ofscience programmes, or & The Science Impact and Advisory
Board, comprising
balance between
discovery
and		 independent
international
experts, regularly
reviews the
translational
science, does not meet		 development
ofstrategic programmes
and JIC impact.
funders'
or stakeholders'
expectations.		 k The executive Research Committee
reviews scientific areas		 of
k JIC fails to deliver the world-leading excellence and horizon scans to identify strategically
science important
scientific areas and opportunities.
&JIC is unable to retain or attract & Strategy and action plans
in place, overseen
by the JIC
suitably
skilled staff to enable
it to		 People &Culture Committee.
sustain
its scientific performance.		 & Career development
programmes
in place to support
high
& In addition to scientific impact, this risk potential
staff.
area could also have an impact on the
level offunding
the institute
is able to
attract.		 & Recruitment
strategy and processes
in place, including
attractive support arrangements.
& Increased
energy prices divert		 & Energy costs are hedged
in the short-term
and specialist
resources from science to advisers
support the institute
with energy procurement.
infrastructure
costs, resulting
in a
reduction
in research
activity and
impact.		 & Energy-saving
opportunities
are actively targeted
and
investment
cases developed,
aligned to net zero carbon
strategic planning.
& High inflation increases research
and
support costs, resulting
in a reduction
in research
activity and impact.		 k The impact ofcost inflation
is regularly
discussed
with funders
with a view to mitigating
the impact on research.
&Cost pressures
mean that the agreed		 & Dedicated
programme
team recruited,
supported
by JIG staff
scope cannot be delivered and professional
consultants
& Insufficient
additional
funding
raised		 & Governance
structure
for programme
implemented,
led		 by
& Vision for NGI Hub not sufficiently Programme
Board and supported
by external assurance
defined or communicated & Workstreams
established
to define Hub vision, engage		 with
& Buildings design do not reflect future external stakeholders
and deliver business change
science requirements
or Hub vision		 & Building design engagement
groups established
& Building works significantly
disrupt		 & Strategy developed
to deliver Net Zero Carbon ambition
science activity during
construction		 & Fundraising
plan being developed
& Project does not achieve
Net Zero
Carbon ambition
&JIC is unable to keep pace with k 5-year investment
plan developed.
developments
in technology
underpinning
its science.		 & Funding
opportunities
identified
and pursued
for technology
investments.
& A major incident disrupts
scientific		 & Business Continuity
and Disaster recovery plans
in place		 and
research
programmes
or		 tested periodically.
administrative
systems.		 & Review ofcompliance
with health &safety and relevant
regulations
from government
agencies and internal
auditors.
& Insurance
arrangements
in place.

Restricted Restricted Restated
Unrestricted general capital Total Total
funds funds funds 2023 2022
Note f000 FOOO FOOO f000 OOOO
Income
Income from charitable activities
Grant income 36,893 91 36,984 34,691
Capital and maintenance grants 831 14,093 14,924 13,420
Other charitable
income		 828 828 705
Income from other tradingactivities
Trading
income		 928 928 491
Rental income 255 255 141
Investment
income		 636 118
Share ofoperating result ofassociates 12 261
Otherincome 3,871 3,871 3,121
Total income 2 6,518 37,724 14,184 58426 52,948
Expenditure
Charitable
activities		 3 (5,335) (38,345) (8,039) (51,719) (44,700)
Raising funds 3 (439) - - (439) (370)
Trading
expenditure		 3 (692) (692) (579)
Other resources expended 3 (344) (344) (245)
Share ofoperating result ofassociates 12 (304) (304)
Total ex enditure 7,114 38,345 8,039 53498 45,894
Net incomel ex enditure for the ear 596 621 6,145 4928 7,054
Transfers
and revaluation
Capital transfers 20 (912) 912
Other transfers 20 193 (65) (128)
Net movement
in funds		 for the ear 1,315 686 6,929 4,928 7,054
Total funds brought
forward as		 previously stated 26,168 794 108,648 135,610 118,782
Prior
ear ad'ustment		 21 36,100 36100 26,326
Funds brought
forward		 as restated 26,168 794 72,548 99,510 92,456
Net movement
in funds for the year		 (1,315) (686) 6,929 4,928 7,054
Funds carried forward 20 24,853 108 79,477 104438 99,510

Restated Restated
Group Group Company Company
2023 2022 2023 2022
Note f000 f000 6000 f000
Fixed assets
Tangible assets 10 73,815 66,983 73,815 66,983
Intangible
assets		 11
Investments 12 1 1
investments
in associates
Share of total assets 1,903 2,590
Share of total liabilities (296) (679)
12 1,607 1,911
Total fixed assets 75422 68,894 73816 66,984
Current assets
Stocks 13 340 283 340 283
Debtors 14 12,201 13,281 12,067 13,224
Cash at bank and
in hand		 15 37,668 42,948 37,444 42,768
50,209 56,512 49,851 56,275
Current
liabilities
Creditors: amounts
falling		 due within one year 16 (21,193) (25,612) (21,096) (25,495)
Total net current assets 29,016 30,900 28,755 30,780
Total assets less current liabilities 104,438 99,794 102,571 97,764
Provisions
for liabilities		 and charges 18 (284) (284)
Total net assets 19 104438 99,510 102571 97,480
The funds ofthe charity
Unrestricted
funds
Fixed assets reserve 20 6,770 7,663 5,752
Designated
reserves		 20 11,705 12,118 12,118
General reserve 20 6,378 6,387 6,267
Total unrestricted
funds		 24,853 26,168 24,137
Restricted funds
General reserve 20 108 794 108 794
Fixed assets reserve 20 68,652 61,231 68,653 61,232
Designated
reserves		 20 10,825 11,317 10,825 11,317
Total restricted
funds		 79,585 73,342 79,586 73,343
Total funds 20 104438 99,510 102571 97,480

Restated
Total Total
2023 2022
6000 f000
Cash flows from operating activities
Net movement
in funds for the year		 4,928 7,054
Share of operating
result of		 associates 304 (261)
Net income/(expenditure)
for		 the year 5,232 6,793
Interest receivable (636) (118)
Depreciation
and amortisation		 8,039 4,799
Capital grants receivable (14,184) (12,184)
Loss on disposal of tangible assets 8 175
Increase
in stocks		 (57) (25)
Decrease in debtors 1,080 4,157
Decrease in creditors (4,419) (7,801)
Decrease in provisions (284)
Net cash used in o eratin activities 5221 4,204
Cash flows from investing activities:
Interest received 636 118
Purchase of tangible assets (14,879) (10,458)
Capital grants received 14,184 12,184
Proceeds from sale of tangible assets 93
Net cash
used
in
/
rovided
b		 investin activities 59 1,937
Chan e in cash and cash e uivalents in the re ortin cried 5280 2,267
Cash and cash equivalents at the beginnning ofthe period 42,948 45,215
Total cash and cash e uivalents at the end ofthe ear 37668 42,948

Research Student Other Total Research Student Other Total
activities activities activities 2023 activities activities activities 2022
FOOO FOOO f000 FOOO f000 FOOO f000 FOOO
Grant income
BBSRC 25,068 2,953 - 28,021 21,445 3,708 25,153
Other government
departments		 1,326 - - 1,326 1,515 34 1,549
European
Union		 2,540 53 - 2,593 3,002 60 3,062
Industrial
partners		 224 11 - 235 943 84 1,027
John Innes Foundation 256 451 - 707 142 436 578
Other charities 2,625 211 - 2,836 2,343 142 2,485
Universities 47 47 27 76 103
Other grants 1,219 - - 1 219 698 36 734
Total
rant income		 33,258 3,726 - 36,984 30,115 4,576 34,691
Capital and maintenance grants
BBSRC
Capital expenditure 14,917 14,917 13,287 13,287
John Innes Foundation
Capital expenditure 7 133 133
Total ca ital
rants		 14,924 14,924 13,420 13,420
Other charitable
income
Scientific services 686 686 633 633
Miscellaneous
income		 142 142 72 72
Total other charitable income 828 828 705 705
Trading
income
John Innes Enterprises Limited 916 916 464 464
Norwich Biosciences Limited 12 12 27 27
Total tradin
income		 928 928 491 491
Rental income
Conferencing
Facilties		 186 186 64 64
Hill House 69 69 77 77
Total rental income 255 255 141 141
Investment
income
Interest receivable
on cash		 deposits 629 629 111 111
Interest receivable
on loan		 to related party 7 7 7 7
Total investment
income		 636 636 118 118
Income from investment in associates 261 261
Total associates income 261 261
Other generated
income
Site infrastructure
recharges		 2,005 2,005 1,520 1,520
Other 1,866 1,866 1,601 1,601
Total other
enerated		 income 3,871 3,871 3,121 3,121
Total income 48,182 3,726 6,518 58,426 43,535 4,576 4,837 52,948

Restated
Research Student Other Total Research Student Other Total
activities activities activities 2023 activities activities activities 2022
Note OOOO OOOO L'000 OOOO OOOO L'000 OOOO KOOO
Direct charitable expenditure:
Staff costs 13,116 13,116 13,639 13,639
Direct costs 12,580 4,196 - 16,776 11,719 3,764 15,483
Depreciation
and		 impairment 8,039 - - 8,039 4,799 4,799
Governance
costs		 4 105 105 107 107
Support costs 4 10,750 2,933 - 13,683 8,128 2,544 10,672
Expenditure
on		 charitable activities 44,485 7,129 105 51,719 38,285 6,308 107 44,700
Raising funds 439 439 370 370
Trading
expenditure		 692 692 579 579
Other resources expended 344 344 245 245
Share of operating result of associates 304 304
Total ex
nditure		 44,485 7,129 1,884 53,498 38,285 6,308 1,301 45,894
Total Total
Ana sis of overnance costs 2023 2022
6000 OOOO
Staff costs 46 35
Travel costs 12 2
Other costs 47 70
Total overnance costs 105 107

4.
ALLOCATIO		 N
O		 F SUPPORT C OSTS, GOV ERNANCE AND RAISING F UNDS
Research Student Raising Governance Total Basis of
activities activities funds costs 2023 Allocation
6000 6000 5000 6000 OOOO
Governing
Council and		 SIAB 60 60 Headcount
Lab management 425 116 541 Headcount
Institute
management		 337 92 429 Headcount
Scientific services 365 100 465 Headcount
Facilities management and utilities* 7,602 2,074 9,676 Headcount
Finance and Purchasing" 538 147 685 Headcount
Computing
and Library*		 635 173 808 Headcount
Human
Resources*		 267 73 340 Headcount
Contracts services* 314 314 Activity
Other support services 581 158 125 909 Activity
Total su
ort costs		 10,750 2,933 439 105 14,227
Research Student Raising Governance Total Basis of
activities activities funds costs 2022 Allocation
OOOO OOOO FOOO FOOO FOOO
Governing
Council and		 SIAB 68 68 Headcount
Lab management 393 123 516 Headcount
Institute
management		 382 120 502 Headcount
Scientific services 93 29 122 Headcount
Facilities management and utilities* 5,469 1,711 7,180 Headcount
Finance and Purchasing* 504 158 662 Headcount
Computing
and Library*		 567 178 745 Headcount
Human
Resources*		 262 82 344 Headcount
Contracts services* 277 277 Activity
Other support services 458 143 93 733 Activity
Total su
ort costs		 8 128 370 107 11149
*Includes services supplied by NBI Partnership Limited (see note 23). Scientific services costs are shown net ofrecharges to
science projects.

Restated
Total Total
2023 2022
f000 f000
Audit services:
Fees payable to the charitable company's auditors for the audit of charitable company and
consolidated
financial
statements		 31 29
Fees payable for the audit of the charitable company's subsidiaries pursuant to legislation 1 1
Depreciation
and amortisation		 8,039 4,799
Loss on disposal of tangible assets 8 175
Hire of plant and equipment 63 65
Rent of land and buildings 41 33
(Profit) on foreign exchange translations (120) (18)

John Innes Norwich John Innes Norwich
Enterprises Biosciences Total Enterprises Biosciences Total
Profit and loss account Limited Limited 2023 Limited Limited 2022
f000 6000 6000 6000 6000 6000
Turnover 916 12 928 464 27 491
Cost of sales 731 731 579 579
Gross profit/(loss) 185 12 197 (115) 27 (88)
Administrative
e
enses
Operating profit/(loss) 185 12 197 (115) 27 (88)
Interest received
0 eratin refit/ loss retained in subsidiar 185 12 197 115 27 88
Net assets at 31 March 258 73 117

Grou and charitable com com an 2023 2022
Number Number
Scientific 328 347
Office mana
ement and		 services 35 31
Total 378
The aggregate
payroll		 costs ofthese persons were:
Grou and charitable com n 2023 2022
Note fOOO f000
Wages and salaries 13,664 13,702
Redundancy
costs		 11 43
Social security costs 1,463 1,393
Other ension costs 23 1,894 2,007
Total 17032 17,145
An analysis ofthe number ofstaff who fall within staff cost bands (ex cluding
pension cost) from f60k upwards
is provid		 ed
below
Grou
and charitable com an		 2023 2022
Number Number
f60,000 - f69,999 20 16
f70,000 - f79,999 11 7
f80,000 - f89,999 4 9
f90,000 - f99,999 7 7
f100,000 - f109,999 5 2
f110,000 - f119,999 2 3
f120,000 - f129,999 1
f130,000 - f139,999
f140,000 - f149,999
f150,000 - f159,999
f160,000 - f169,999
f170,000 - f179,999
f220,000 - f229,999
Total 55 49

10.TANGIBLE ASS ETS
Long Plant,
Freehold leasehold machinery Assets
land and land and and under Restated
Grou
6Com
an		 Note buildin s buildin
s		 e ui
ment		 construction Total
f000 LOOO LOOO f000 6000
Cost/Valuation
Brought forward as previously stated 3,771 72,318 52,972 2,371 131,432
Prior
ear ad'ustment		 21 4,822 4 822
Restated at 1 April 2022 3,771 67,496 52,972 2,371 126,610
Transfers 49 118 1,989 (2,156)
Additions 418 7,499 6,962 14,879
Dis osals 797 8 805
At 31 March 2023 3,820 68,032 61,663 7,169 140,684
Accumulated
Depreciation
Brought forward as previously stated 824 27,525 28,349
Prior
ear ad'ustment		 21 31,278 31278
Restated at 1 April 2022 824 31,278 27,525 59,627
Charge for the year 5 2,622 5,412 8,039
Dis osals 797 797
At 31 March 2023 829 33900 32140 66869
Net book value at 31 March 2023 2 991 34132 29523 7 169 73815
Restated
net book value at 31		 March 2022 2,947 36,218 25,447 2,371 66,983

Registration Country of Class and percentage Class and percentage of
Subsidia Undertakin number re istration Princi
al activit		 shares held
John Innes Enterprises
Limited		 02549904 England Contract research 100%ordinary shares
Norwich Biosciences Limited 03076575 England Management
of		 intellectual property 100%ordinary shares
Norwich Research
Limited		 02814101 England Dormant 100%ordinary shares
JIC NRP Capital
Limited		 06145922 England Member ofAnglia Innovation Partnership LLP 100%ordinary shares
The registered
address for all the subsidiaries
is John		 innes Centre, Norwich Research Park, Colney, Norwich,
NR4		 7UH.

The move ment
in the value of investments
during the year was as follows:
Total Total
2023 2022
6000 f000
Valuation
At beginning of year
Acquisition
Im airment
Atend of ear
Historical cost
As at 1 rll 2022 and 31 March 2023 1 631 1,631

Leaf Leaf
Expression Plant Expression Plant
Systems Bioscience Total Systems Bioscience Total
Grou Limited Limited 2023 Limited Limited 2022
f000 OOOO f000 f000 OOOO OOOO
Associates, share of:
Turnover 391 391 1,237 1,237
Operating
(loss)/profit		 (233) (233) 261 261
Movement
in o enin		 balance 71 71
Share of result for the ear 304 304 261 261
The Group's investment in associates is represented as follows:
Leaf Leaf
Expression Plant Expression Plant
Systems Bioscience Total Systems Bioscience Total
Grou Limited Limited 2023 Limited Limited 2022
f000 f000 6000 f000 f000 OOOO
Associates: Share of net assets
At beginning of year 1,911 1,911 1,650 1,650
Additions
Impairment provision
Share of result for the ear 304 304 261 261
At end of ear 1,607 1 607 1,911 1 911
Represented by:
Share of total assets 1,903 1,903 2,590 2,590
Share of total liabilities 296 296 679 679
Share of net assets 1,607 1 607 1,911 1 911

Total Total
Grou and charitable com an 2023 2022
6000 f000
Raw materials and consumables 340 283
Total 340 283

Group Group Company Company
2023 2022 2023 2022
Note 6000 f000 6000 f000
Grants receivable:
from government bodies 24 2,187 4,219 2,187 4,219
from other sources 2,684 2,467 2,684 2,467
Trade debtors 2,764 1,465 2,418 1,297
Amounts
owed		 by subsidiary undertakings 253 139
Amounts
owed		 by other related parties 24 951 1,054 942 1,054
Other debtors 559 961 559 934
Pre a ments and accrued income 3056 3,115 3024 3,114
Total amounts fallin due within one ear 12201 13,281 12067 13,224

15. C ASH AT BANK AND IN HAND
Group Group Company Company
2023 2022 2023 2022
6000 f000 6000 f000
Cash at bank 37,666 42,945 37,442 42,765
Cash in hand 2 3 2 3
Total 37668 42,948 37444 42,768

Group Group Company Company
2023 2022 2023 2022
Note 6000 f000 6000 f000
Grants received in advance:
from government
bodies		 24 5,345 6,285 5,345 6,285
from other sources 3,995 4,576 3,958 4,493
Trade creditors 3,686 3,475 3,686 3,464
Amounts
owed to subsidiary		 undertakings 1
Amounts
owed to other		 related parties 24 896 1,107 896 1,107
Other creditors 1,210 1,838 1,148 1,829
Taxation and social security 353 369 353 369
Accruals and deferred income 5708 7,962 5709 7,948
Total amounts
fallin		 due within one ear 21 193 25,612 21 096 25,495

Total Total
Grou and charitable com an 2023 2022
Note 6000 OOOO
Grants receivable 14 4871 6 686
Grants received
in advance		 16 9340 10,861
Net rants received in advance 4469 4,175
Net grants received
in		 advance at beginning ofyear (4,175) (2,722)
Grant monies received during
the year		 (52,202) (49,564)
Grant mone
released		 to SOFA durin the ear 51908 48,111
Net rants received in advance 4,469 4,175

Total Total
Grou
and charitable		 com an 2023 2022
f000 f000
Restructuring
provision		 at beginning ofyear 284
Charge
in		 the year
Released in the year (284)
Nilised
Provision at end of ear 284

Fixed Net current Total
assets assets 2023
f000 f000 6000
Group
Unrestricted:
Fixed assets reserve 6,770 6,770
Designated capital reserve 11,705 11,705
General 6,378 6,378
Restricted:
General reserve 108 108
Fixed assets reserve 66,652 68,652
Designated capital reserve 10,825 10,825
Net assets 75422 29016 104438
Charitable company
Unrestricted:
Fixed assets reserve 5,163 5,163
Designated capital reserve 11,705 11,705
General 6,117 6,117
Restricted:
General reserve 108 108
Fixed assets reserve 68,653 68,653
Designated capital reserve 10,825 10,825
Net assets 73816 28 755 102571

Creditors
over one Restated
Fixed Net current year and Total
assets assets rovisions 2022
f000 FOOO f000 6000
Group
Unrestricted:
Fixed assets reserve 7,663 7,663
Designated capital reserve 12,118 12,118
General 6,671 (284) 6,387
Restricted:
General reserve 794
Fixed assets reserve 61,231 61,231
Designated capital reserve 11,317 11,317
Net assets 68894 30900 284 99510
Charitable company
Unrestricted:
Fixed assets reserve 5,752 5,752
Designated capital reserve 12,118 12,118
General 6,551 (284) 6,267
Restricted:
General reserve 794
Fixed assets reserve 61,232 61,232
Designated capital reserve 11,317 11,317
Net assets 66984 30780 284 97480

Unrestricted Restricted
fixed Unrestricted Unrestricted Restricted fixed Restricted Total
assets designated general general assets designated 2023
FOOO FOOO OOOO FOOO FOOO FOOO OOOO
Group
At 1 April 2022 7,663 12,118 6,387 794 61,231 11,317 99,510
Total income and expenditure for the year (596) (621) 6,145 4,928
Associates (304) 304
Capital transfers (920) 1,284 (364)
Centre funded
capital		 331 (331) 8 (8)
Other transfers 82 275 65 128
At 31 March 2023 6,770 11,705 6,378 108 68,652 10,825 104438
Charitable
company
At 1 April 2022 5,752 12,118 6,267 794 61,232 11,317 97,480
Total income and expenditure for the year (514) (540) 6,145 5,091
Capital transfers (920) 1,284 (364)
Centre funded
capital		 331 (331) 8 (8)
Other transfers 82 356 146 128
At 31 March 2023 5,163 11,705 6,117 108 68,653 10,825 102571
Unrestricted Restricted Restated
fixed Unrestricted Unrestricted Restricted fixed Restricted Total
assets desi nated eneral eneral assets desi nated 2022
FOOO FOOO f000 f000 FOOO FOOO FOOO
Group
At 1 April 2021 7,994 12,645 7,266 48 55,248 9,255 92,456
Total income and expenditure for the year 274 (605) 7,385 - 7,054
Associates 261 (261)
Capital transfers (624) (36) 660
Centre funded
capital		 32 (300) 268 (2,062) 2,062
Other transfers 227 1,160 1,387
At 31 March 2022 7,663 12,118 6,387 794 61,231 11,317 99510
Charitable
company
At 1 April 2021 6,344 12,645 7,028 48 55,486 9,255 90,806
Total income and expenditure for the year 159 (633) 7,148 6,674
Capital transfers (624) (36) 660
Centre funded
capital		 32 (300) 268 (2,062) 2,062
Other transfers 227 1,188 1,415
At 31 March 2022 5,752 12,118 6,267 794 61,232 11,317 97480

Restated
Total Total
Grou
and charitable
com an		 2023 2022
f000 f000
Capital commitments at the end of the financial year for which no provision has been made:
Contracted 5382 5,031
Amounts due under other operating leases for plant and machinery:
Expiring in less than one year 44 36
Expiring between one and two years 28 32
Expiring betveen two and five years 13 16
E
irin		 over five ears 2
87

IF is a mem
ransactions		 ber ofthe charitable
company
and
it nominates
one Go
took place during the year:		 vernor to the Governing
Council ofJIC. The follow		 ing
Restated
Total Total
2023 2022
OOOO f000
Paid toJIC:
Grants for studentships 471 436
Grants for research project 150 142
Contribution to salary costs 27 39
Contribution to other costs 52 3
Contribution to ca ital costs 7 133
707 753